2016
Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL
Freeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, Al-Ahmad A, Turakhia MP. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circulation Arrhythmia And Electrophysiology 2016, 9: e003407. PMID: 27307517, PMCID: PMC4911813, DOI: 10.1161/circep.115.003407.Peer-Reviewed Original ResearchConceptsLAA closureLeft atrial appendageQuality-adjusted life yearsPROTECT AFAtrial fibrillationPercutaneous closureWatchman deviceAtrial appendageLife yearsTrial dataWATCHMAN LAA closure devicePROTECT AF trialIncremental cost-effectiveness ratioMajor adverse eventsPrevention of strokeAtrial appendage closureProspective Randomized EvaluationLAA closure deviceLong-term trial resultsQuality-adjusted survivalCost-effectiveness ratioCost-effectiveness resultsMedical anticoagulationAF trialAdverse events
2010
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Annals Of Internal Medicine 2010, 154: 1-11. PMID: 21041570, DOI: 10.7326/0003-4819-154-1-201101040-00289.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnticoagulantsAtrial FibrillationBenzimidazolesBeta-AlanineCost-Benefit AnalysisDabigatranFibrinolytic AgentsHemorrhageHumansIntracranial HemorrhagesIschemic Attack, TransientMarkov ChainsMyocardial InfarctionQuality-Adjusted Life YearsRisk FactorsSensitivity and SpecificityStrokeWarfarinConceptsHigh-dose dabigatranIncremental cost-effectiveness ratioNonvalvular atrial fibrillationLow-dose dabigatranCost-effectiveness ratioAtrial fibrillationIschemic strokeCost of dabigatranIntracranial hemorrhageClinical trialsOral direct thrombin inhibitorVeterans Affairs Health Services ResearchSingle randomized clinical trialAdjusted-dose warfarinStudies of anticoagulationPatients 65 yearsRE-LY trialDirect thrombin inhibitorRandomized clinical trialsAmerican Heart AssociationQuality-adjusted life expectancyQuality-adjusted survivalBase-case analysisHealth services researchStroke prevention